
New positive microbiome results for IBS-C
EnteroBiotix, a clinical-stage biopharmaceutical company developing best-in-class drugs for gut health, has announced positive initial results with EBX-102-02, the company’s next-generation full-spectrum microbiome product, from the TrIuMPH Phase IIa clinical trial in adults with irritable bowel syndrome with constipation (IBS-C). The multicentre, randomised, double-blind, placebo-controlled TrIuMPH (Treating IBS with an… Read More












